New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 14, 2014
07:22 EDTSUPNSupernus price target raised to $14 from $12 at Stifel
After Supernus stated that it believes it is on track to reach cash flow break-even, Stifel thinks the launches of the company's Oxtellar and Trokendi drugs are going well. Stifel believes that uptake of the company's Trokendi XR drug could improve, and it keeps a Buy rating on the stock.
News For SUPN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 12, 2014
09:21 EDTSUPNOn The Fly: Pre-market Movers
Subscribe for More Information
November 11, 2014
16:38 EDTSUPNSupernus expects to be profitable in 2015
Subscribe for More Information
16:34 EDTSUPNSupernus updates progress of product candidates
Subscribe for More Information
16:33 EDTSUPNSupernus raises FY14 revenue view to $115M-$118M from $105M
FY14 consensus $104.44M. The company is reducing its cash burn guidance for the year from $5M-10M to approximately $5M, and raising its guidance for year end cash and marketable securities to approximately $85M. The company anticipates achieving cash flow break even by year end and being profitable in 2015.
16:32 EDTSUPNSupernus reports Q3 EPS 39c, consensus 36c
Reports Q3 revenue $52.5M, consensus $43.08M.
November 7, 2014
07:37 EDTSUPNSupernus issued fourth U.S. patent for Trokendi XR
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use